Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Why is Shijiazhuang Yiling Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -4.17% and Operating profit at -194.82% over the last 5 years

The company has declared Negative results for the last 7 consecutive quarters

NET SALES(HY) At CNY 2,448.61 MM has Grown at -41.66%
NET PROFIT(HY) At CNY -914.48 MM has Grown at -751.49%
ROCE(HY) Lowest at -6.3%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 7.14%, its profits have fallen by -338.5%
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Shijiazhuang Yiling Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shijiazhuang Yiling Pharmaceutical Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

5.76%

0.25

31.42%

China Shanghai Composite

14.77%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-4.17%

EBIT Growth (5y)

-194.82%

EBIT to Interest (avg)

49.58

Debt to EBITDA (avg)

0.16

Net Debt to Equity (avg)

-0.10

Sales to Capital Employed (avg)

0.72

Tax Ratio

8.08%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

13.68%

ROE (avg)

11.15%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.02

EV to EBIT

-27.88

EV to EBITDA

-177.66

EV to Capital Employed

2.18

EV to Sales

3.50

PEG Ratio

Dividend Yield

ROCE (Latest)

-7.82%

ROE (Latest)

-5.21%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Sideways

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

NET SALES(Q)

At CNY 2,327.98 MM has Grown at 45.65%

RAW MATERIAL COST(Y)

Fallen by -10.29% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -9.6 %

PRE-TAX PROFIT(Q)

Highest at CNY 394.12 MM

NET PROFIT(Q)

Highest at CNY 325.95 MM

EPS(Q)

Highest at CNY 0.2

-23What is not working for the Company

NET SALES(HY)

At CNY 2,448.61 MM has Grown at -41.66%

NET PROFIT(HY)

At CNY -914.48 MM has Grown at -751.49%

ROCE(HY)

Lowest at -6.3%

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.4%

CASH AND EQV(HY)

Lowest at CNY 2,019.2 MM

Here's what is working for Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 394.12 MM has Grown at 297.02%

over average net sales of the previous four periods of CNY -200.05 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 325.95 MM has Grown at 281.85%

over average net sales of the previous four periods of CNY -179.24 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales

At CNY 2,327.98 MM has Grown at 45.65%

over average net sales of the previous four periods of CNY 1,598.38 MM

MOJO Watch

Near term sales trend is very positive

Net Sales (CNY MM)

Pre-Tax Profit

Highest at CNY 394.12 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 325.95 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.2

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Debt-Equity Ratio

Lowest at -9.6 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -10.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Debtors Turnover Ratio

Lowest at 2.4% and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Cash and Eqv

Lowest at CNY 2,019.2 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents